{"id":{"repo_id":"denver","oai_identifier":"oai:digitalcommons.du.edu:etd-2950"},"canonical_url":"https://search.ndltd.org/etd/denver/oai:digitalcommons.du.edu:etd-2950","repository":{"repo_id":"denver","name":"University of Denver","base_url":"https://digitalcommons.du.edu/do/oai/"},"display":{"title":"The Place and Role of Pharmacy Benefit Management (PBM) Companies in US Healthcare System","abstract":"On average, prescription drugs cost US consumers more than any other developed country in the world. US drug makers claim that intermediaries in the prescription drug supply chain, companies called pharmacy benefit managers (PBM), are forcing them to increase their drug prices. PBMs counter that the discounts they receive from drug makers are channeled to insurers. This thesis will examine the role that PBMs play in the prescription drug supply chain and determine what effect they have on drug prices. This thesis will utilize a comparative static model, Structure, Conduct, Performance (SCP) framework to analyze the pharmaceutical manufacturing and the PBM markets. Given the limitations of comparative static analysis, this thesis will critically evaluate the conclusion of the SCP framework and provide a more contextualized alternative. While the PBMs profit from high drug prices, drug manufacturers are the leading cause behind increasing drug costs in the US.","abstract_html":"On average, prescription drugs cost US consumers more than any other developed country in the world. US drug makers claim that intermediaries in the prescription drug supply chain, companies called pharmacy benefit managers (PBM), are forcing them to increase their drug prices. PBMs counter that the discounts they receive from drug makers are channeled to insurers. This thesis will examine the role that PBMs play in the prescription drug supply chain and determine what effect they have on drug prices. This thesis will utilize a comparative static model, Structure, Conduct, Performance (SCP) framework to analyze the pharmaceutical manufacturing and the PBM markets. Given the limitations of comparative static analysis, this thesis will critically evaluate the conclusion of the SCP framework and provide a more contextualized alternative. While the PBMs profit from high drug prices, drug manufacturers are the leading cause behind increasing drug costs in the US.","abstract_has_math":false,"creators":["Mattis, George, II"],"institution":null,"degree_name":"M.A.","degree_level":"Masters Thesis","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Henning Schwardt","Yavuz Yasar","Chiara Piovani","Alejandro Cerón Valdes"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T07:54:02Z","subjects":["Health care","Pharmacy","Economics","Health and Medical Administration","Medicine and Health Sciences","Other Economics","Pharmacy Administration, Policy and Regulation"],"languages":["en"],"rights":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>","George Mattis, II"],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.du.edu/etd/1958","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.du.edu/etd/1958","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.du.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.du.edu%3Aetd-2950","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Henning Schwardt","Yavuz Yasar","Chiara Piovani","Alejandro Cerón Valdes"]},{"key":"dc:creator","label":"Author","values":["Mattis, George, II"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-02-01T08:00:00Z"]},{"key":"dc:date.copyright","label":"Dc Date Copyright","values":["2021-01-01T08:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2021-01-01T08:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Masters Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M.A."]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Health care","Pharmacy","Economics","Health and Medical Administration","Medicine and Health Sciences","Other Economics","Pharmacy Administration, Policy and Regulation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>"]},{"key":"dc:rights.holder","label":"Dc Rights Holder","values":["George Mattis, II"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.du.edu/etd/1958"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["On average, prescription drugs cost US consumers more than any other developed country in the world. US drug makers claim that intermediaries in the prescription drug supply chain, companies called pharmacy benefit managers (PBM), are forcing them to increase their drug prices. PBMs counter that the discounts they receive from drug makers are channeled to insurers. This thesis will examine the role that PBMs play in the prescription drug supply chain and determine what effect they have on drug prices. This thesis will utilize a comparative static model, Structure, Conduct, Performance (SCP) framework to analyze the pharmaceutical manufacturing and the PBM markets. Given the limitations of comparative static analysis, this thesis will critically evaluate the conclusion of the SCP framework and provide a more contextualized alternative. While the PBMs profit from high drug prices, drug manufacturers are the leading cause behind increasing drug costs in the US."]},{"key":"dc:description.provenance","label":"Dc Description Provenance","values":["Received from ProQuest"]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:format.extent","label":"Dc Format Extent","values":["76 pgs"]},{"key":"dc:title","label":"Title","values":["The Place and Role of Pharmacy Benefit Management (PBM) Companies in US Healthcare System"]}]}],"canonical_facts":{"dc:contributor":["Henning Schwardt","Yavuz Yasar","Chiara Piovani","Alejandro Cerón Valdes"],"dc:creator":["Mattis, George, II"],"dc:date.available":["2022-02-01T08:00:00Z"],"dc:date.copyright":["2021-01-01T08:00:00Z"],"dc:date.created":["2021-01-01T08:00:00Z"],"dc:description.abstract":["On average, prescription drugs cost US consumers more than any other developed country in the world. US drug makers claim that intermediaries in the prescription drug supply chain, companies called pharmacy benefit managers (PBM), are forcing them to increase their drug prices. PBMs counter that the discounts they receive from drug makers are channeled to insurers. This thesis will examine the role that PBMs play in the prescription drug supply chain and determine what effect they have on drug prices. This thesis will utilize a comparative static model, Structure, Conduct, Performance (SCP) framework to analyze the pharmaceutical manufacturing and the PBM markets. Given the limitations of comparative static analysis, this thesis will critically evaluate the conclusion of the SCP framework and provide a more contextualized alternative. While the PBMs profit from high drug prices, drug manufacturers are the leading cause behind increasing drug costs in the US."],"dc:description.provenance":["Received from ProQuest"],"dc:format":["application/pdf"],"dc:format.extent":["76 pgs"],"dc:identifier":["https://digitalcommons.du.edu/etd/1958"],"dc:language":["en"],"dc:rights":["<p>Copyright is held by the author. User is responsible for all copyright compliance.</p>"],"dc:rights.holder":["George Mattis, II"],"dc:subject":["Health care","Pharmacy","Economics","Health and Medical Administration","Medicine and Health Sciences","Other Economics","Pharmacy Administration, Policy and Regulation"],"dc:title":["The Place and Role of Pharmacy Benefit Management (PBM) Companies in US Healthcare System"],"thesis:degree_level":["Masters Thesis"],"thesis:degree_name":["M.A."]},"updated_at":"2026-11-19T07:54:02Z"}